kidney disease glp 1 GLP-1 receptor agonist versus DPP-4 inhibitor and and cardiovascular outcomes in clinical practice in type-2 diabetes Renal effects of GLP-1 receptor

Regarding the inclusion of preprints, its inclusion was carefully justified to reflect cutting-edge developments, and we emphasize that its preliminary nature does not detract from the overall evidence base

President Donald Trump promised from the White House Thursday that Novo Nordisks Ozempic will cost about $150 when he and Centers for Medicare & Medicaid Services Administrator Mehmet Oz are done negotiating with the company

PMID 25519934

Thats still a solid number, especially when appetite is tiny

KEY FINDINGS BAR (8 stat cards) STAT 1: $150B - projected global category size by 2030 STAT 2: ~58% - of total category AI citation share captured by six pharma brands STAT 3: 2 - companies (Novo Nordisk and Eli Lilly) own nearly 100% of GLP-1 citations STAT 4: ~13% - AI Overview trigger rate on health queries, highest of any consumer category STAT 5: 60-70% - share of "best diet app" AI answers citing MyFitnessPal first STAT 6: 200M+ - registered MyFitnessPal user base, the informational moat behind its citation lock STAT 7: 60+ - consumer prompts tracked across ChatGPT, Claude, Perplexity, and Google AI Overviews to build the index STAT 8: 25 - brands ranked, with the remaining ~11% citation share split across ranks 16-25 and unranked brands THE TOP 15 BY AI CITATION SHARE Estimated share of citations across 60+ weight-loss-related consumer prompts run through ChatGPT, Claude, Perplexity, and Google AI Overviews, Q1 2026